MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
Josép María
Ribera Santasusana
Publicaciones en las que colabora con Josép María Ribera Santasusana (13)
2021
-
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Leukemia, Vol. 35, Núm. 12, pp. 3585-3588
2017
-
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome
Hematological Oncology, Vol. 35, Núm. 4, pp. 520-527
2012
-
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/ Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Haematologica, Vol. 97, Núm. 2, pp. 310-317
2010
-
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328
-
Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source
Biology of Blood and Marrow Transplantation, Vol. 16, Núm. 7, pp. 957-966
2009
-
Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study
Haematologica, Vol. 94, Núm. 9, pp. 1282-1288
2008
-
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival
Journal of Clinical Oncology, Vol. 26, Núm. 4, pp. 577-584
2007
-
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
British Journal of Haematology, Vol. 139, Núm. 1, pp. 70-80
-
Sirolimus as Part of Immunosuppressive Therapy for Refractory Chronic Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 13, Núm. 6, pp. 701-706
2006
-
Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: Influence of stem cell source [13]
Leukemia
-
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol
Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183